Moleculin secures Mexican patent for lung-targeted liposomal Annamycin through 2040

Moleculin Biotech, Inc.

Mexican Patent Office granted Patent No. 436849 for lung-targeted liposomal Annamycin; expires Nov 23, 2040.
Patent strengthens global IP for Annamycin, now in pivotal MIRACLE trial for relapsed/refractory AML.
Issued 888,400 shares via ATM in Sept 2026 for $0.48M gross proceeds; shares outstanding now 20,385,780.
Series I warrant exercise price reduced from $0.75 to $0.51 per share due to anti-dilution after ATM issuance.
CEO Walter Klemp cites patent as reinforcing long-term commercial potential of Annamycin platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.